Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
| العنوان: | Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects |
|---|---|
| المؤلفون: | Sergio Rizzo, Marta Castiglia, Christian Rolfo, Jan P. van Meerbeeck, Giuseppe Cicero, Patrick Pauwels, Francesco Passiglia, Giuseppe Bronte, Francesca Lo Vullo, Antionio Russo, Elisa Giovannetti, Eugenio Fiorentino |
| المساهمون: | Bronte, G, Rolfo, C, Giovannetti, E, Cicero, G, Pauwels, P, Passiglia, F, Castiglia, M, Rizzo, S, Lo Vullo, F, Fiorentino, E, Van Meerbeeck, J, Russo, A, Medical oncology laboratory, CCA - Innovative therapy |
| المصدر: | Bronte, G, Rolfo, C, Giovannetti, E, Cicero, G, Pauwels, P, Passiglia, F, Castiglia, M, Rizzo, S, Lo Vullo, F, Fiorentino, E, van Meerbeeck, J & Russo, A 2014, ' Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects ', Critical Reviews in Oncology / Hematology, vol. 89, no. 2, pp. 300-313 . https://doi.org/10.1016/j.critrevonc.2013.08.003Test Critical Reviews in Oncology / Hematology, 89(2), 300-313. Elsevier Ireland Ltd Critical reviews in oncology, hematology |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Lung Neoplasms, EGFR, Erlotinib, Gefitinib, Lung cancer, NSCLC, Tyrosine kinase, Settore MED/06 - Oncologia Medica, Antineoplastic Agents, medicine.disease_cause, Erlotinib Hydrochloride, Growth factor receptor, Pharmacokinetics, Carcinoma, Non-Small-Cell Lung, Internal medicine, Humans, Medicine, Lung, Protein Kinase Inhibitors, neoplasms, business.industry, Hematology, Oncogene Addiction, medicine.disease, respiratory tract diseases, ErbB Receptors, Quinazolines, Human medicine, business, Carcinogenesis, medicine.drug |
| الوصف: | Gefitinib and erlotinib are the two anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) approved for treatment of advanced NSCLC patients. These drugs target one of the most important pathways in lung carcinogenesis and are able to exploit the phenomenon of 'oncogene addiction', with different efficacy according to EGFR gene mutational status in tumor samples. Gefitinib has been approved only for EGFR mutation bearing patients regardless the line of treatment, while erlotinib is also indicated in patients without EGFR mutation who undergo second- or third-line treatment. Some studies evaluated the main differences between these drugs both for direct comparison and to improve their sequential use. In particular, toxicity profile resulted partially different, and these observations may be explained by several molecular and pharmacoldnetic features. Therefore, this review integrates preclinical data with clinical evidences of TKIs to guide the optimization of currently available treatments in advanced NSCLC patients. (C) 2013 Published by Elsevier Ireland Ltd. |
| تدمد: | 1040-8428 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cd84ee94799c56934c065ab33b14bdcTest https://research.vumc.nl/en/publications/75a54b5d-18f2-46c0-bf46-4c2f125e47dcTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7cd84ee94799c56934c065ab33b14bdc |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10408428 |
|---|